Commence enrollment for Cohort B of the HOPE-3 trial
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 14 Nov 2023
- Due
- 31 Dec 2023
- Delivered
- 11 Dec 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Expect to commence enrollment for Cohort B in the fourth quarter of 2023.”
What we found
Evidence strength B What the grades mean
Capricor commenced enrollment for HOPE-3 Cohort B in Q4 2023, announcing on December 11, 2023 that enrollment had been initiated.
-
B Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis
“Enrollment has commenced for Cohort B which is designed to enroll approximately 44 participants randomized to either CAP-1002 or placebo in a 1:1 ratio.” ✓ confirmed on the page
-
B Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis
“Enrollment has commenced for Cohort B which is designed to enroll approximately 44 participants randomized to either CAP-1002 or placebo in a 1:1 ratio.” ✓ confirmed on the page
-
B Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
“began clinical dosing of Cohort B of the HOPE-3 trial from our San Diego facility” ✓ confirmed on the page
Checked 4 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Commence
- Deliverable
- Enrollment for Cohort B
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Capricor Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-CAPR-002536 · Corrections policy